Hydrogen-Peroxide Synthesis and LDL-Uptake Controls Immunosuppressive Properties in Monocyte-Derived Dendritic Cells.
IDO
LDL-uptake
catalase
hydrogen peroxide
reactive oxygen species
tolerogenic dendritic cells
tumor immune escape
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
26 Jan 2021
26 Jan 2021
Historique:
received:
16
12
2020
revised:
16
01
2021
accepted:
21
01
2021
entrez:
3
2
2021
pubmed:
4
2
2021
medline:
4
2
2021
Statut:
epublish
Résumé
Induction of myeloid-derived suppressor cells (MDSC) is a critical step in immune cell evasion by different cancer types, including liver cancer. In the liver, hepatic stromal cells orchestrate induction of MDSCs, employing a mechanism dependent on hydrogen peroxide (H Monocytes from healthy donors were differentiated to moDCs in the presence of extracellular enzymatic H CAT-DCs were of an immature DC phenotype, particularly characterized by impaired expression of the costimulatory molecules CD80/86. Moreover, CAT-DCs were able to suppress T-cells using indoleamine 2,3-dioxygenase (IDO), and induced IL10/IL17-secreting T-cells-a subtype reported to exert immunosuppression in acute myeloid leukemia. CAT-DCs also displayed significantly increased NADPH-oxidase-driven H Here, we report a novel axis between H
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Induction of myeloid-derived suppressor cells (MDSC) is a critical step in immune cell evasion by different cancer types, including liver cancer. In the liver, hepatic stromal cells orchestrate induction of MDSCs, employing a mechanism dependent on hydrogen peroxide (H
METHODS
METHODS
Monocytes from healthy donors were differentiated to moDCs in the presence of extracellular enzymatic H
RESULTS
RESULTS
CAT-DCs were of an immature DC phenotype, particularly characterized by impaired expression of the costimulatory molecules CD80/86. Moreover, CAT-DCs were able to suppress T-cells using indoleamine 2,3-dioxygenase (IDO), and induced IL10/IL17-secreting T-cells-a subtype reported to exert immunosuppression in acute myeloid leukemia. CAT-DCs also displayed significantly increased NADPH-oxidase-driven H
DISCUSSION
CONCLUSIONS
Here, we report a novel axis between H
Identifiants
pubmed: 33530408
pii: cancers13030461
doi: 10.3390/cancers13030461
pmc: PMC7865547
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Staedtler Stiftung
ID : Mackensen, Resheq
Organisme : Erich und Gertrud Roggenbuck-Stiftung
ID : N/A
Organisme : ELAN Fonds Erlangen
ID : N/A
Références
Nat Med. 2010 Aug;16(8):880-6
pubmed: 20622859
Cancer Lett. 2018 Feb 1;414:127-135
pubmed: 29126914
Br J Cancer. 2003 Nov 17;89(10):1822-6
pubmed: 14612885
Cancer Immunol Res. 2017 Jan;5(1):3-8
pubmed: 28052991
Front Immunol. 2013 Dec 02;4:419
pubmed: 24348482
Nat Rev Immunol. 2010 Apr;10(4):248-56
pubmed: 20336152
Cancer Cell. 2015 Feb 9;27(2):156-7
pubmed: 25670075
Circ Res. 1999 Nov 12;85(10):950-8
pubmed: 10559142
J Transl Med. 2015 Jul 15;13:229
pubmed: 26174551
JCI Insight. 2017 Apr 20;2(8):
pubmed: 28422751
Biomark Insights. 2018 Feb 06;13:1177271918755391
pubmed: 29449774
Mol Neurobiol. 2004 Apr;29(2):167-78
pubmed: 15126684
Cancer Res. 2006 Jan 15;66(2):1123-31
pubmed: 16424049
Clin Cancer Res. 1998 Mar;4(3):585-93
pubmed: 9533525
Nature. 1998 Mar 19;392(6673):245-52
pubmed: 9521319
Nature. 1987 Aug 13-19;328(6131):626-9
pubmed: 3112582
Surgery. 2002 Jan;131(1):85-91
pubmed: 11812968
Int J Cell Biol. 2012;2012:762825
pubmed: 22666258
Oncogenesis. 2016 Feb 22;5:e198
pubmed: 26900950
J Immunol. 1998 Feb 15;160(4):1831-40
pubmed: 9469444
Biochim Biophys Acta. 2014 Apr;1845(2):182-201
pubmed: 24440852
Biochemistry (Mosc). 2006 Jan;71(1):60-7
pubmed: 16457620
Am J Physiol Lung Cell Mol Physiol. 2010 Feb;298(2):L127-30
pubmed: 19915158
Curr Opin Immunol. 1997 Feb;9(1):10-6
pubmed: 9039784
Cancer Prev Res (Phila). 2012 May;5(5):701-5
pubmed: 22490437
Methods Enzymol. 2013;528:269-78
pubmed: 23849871
Clin Nephrol. 2010 Mar;73(3):221-8
pubmed: 20178722
Nat Rev Immunol. 2015 Nov;15(11):669-82
pubmed: 26471778
Redox Biol. 2015 Dec;6:353-371
pubmed: 26342455
Front Immunol. 2017 Mar 08;8:248
pubmed: 28337200
Blood. 2005 Oct 1;106(7):2375-81
pubmed: 15947091
J Am Chem Soc. 2009 Aug 26;131(33):11751-61
pubmed: 19653683
Free Radic Res. 2010 May;44(5):479-96
pubmed: 20370557
J Urol. 1998 Jul;160(1):214-9
pubmed: 9628653
Cell. 2015 Jun 18;161(7):1527-38
pubmed: 26073941
Nat Rev Drug Discov. 2017 Jan;16(1):35-52
pubmed: 27811929
Biochem Pharmacol. 2009 Apr 15;77(8):1316-27
pubmed: 19101522
Cancer Res. 2012 Jul 1;72(13):3125-30
pubmed: 22721837
Immunol Cell Biol. 2017 Mar;95(3):244-251
pubmed: 27748730
Blood. 2009 Oct 8;114(15):3235-43
pubmed: 19625705
J Exp Med. 2016 Jan 11;213(1):15-23
pubmed: 26694970
Clin Rheumatol. 2008 Feb;27(2):141-5
pubmed: 17912575
J Immunol. 2015 Mar 15;194(6):2578-86
pubmed: 25667417
Clin Cancer Res. 2015 Feb 15;21(4):687-92
pubmed: 25501578
Immunology. 2018 May;154(1):3-20
pubmed: 29313948
Biochem Biophys Res Commun. 2010 Nov 26;402(4):663-9
pubmed: 20971061
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Front Immunol. 2014 Oct 17;5:514
pubmed: 25368618
Cytokine Growth Factor Rev. 2017 Jun;35:15-25
pubmed: 28442214
Cell Mol Immunol. 2020 Jan;17(1):95-107
pubmed: 30842629
Immunology. 2001 Jun;103(2):131-6
pubmed: 11412299
Cancer Lett. 2015 Oct 28;367(2):103-7
pubmed: 26188281
Prostate. 2001 Jan 1;46(1):68-75
pubmed: 11170134
Mol Cancer. 2019 Jan 15;18(1):10
pubmed: 30646912
Cell. 2015 Sep 10;162(6):1257-70
pubmed: 26343581